Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06851559 · ClinicalTrials.gov registry record · Phase 2
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Phathom Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT06851559 is a Phase 2 study of Eosinophilic Esophagitis that is actively recruiting participants, run by Phathom Pharmaceuticals. The registered enrollment target is 80 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06851559, a Phase 2 study of Eosinophilic Esophagitis, is actively recruiting participants, sponsored by Phathom Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vonoprazan
Study Locations (20)
Florida
- Nature Coast Clinical Research - Inverness
- Encore Borland-Groover Clinical Research - Jacksonville
- International Center for Research - Tampa
California
- GW Research, Inc - Chula Vista
- Southern California Research Institute Medical Group - Los Angeles
Colorado
- Rocky Mountain Gastroenterology - Lakewood
- Western States Clinical Research, Inc. - Wheat Ridge
Idaho
- Treasure Valley Medical Research - Boise
- Grand Teton Research Group - Idaho Falls
Illinois
- Northwestern Medicine Digestive Health Center - Chicago
- GI Alliance - Gurnee - Gurnee
Louisiana
- Combined Gastro, LLC - Lafayette
- Tandem Clinical Research GI, LLC - Marrero
Arkansas
- Preferred Research Partners, Inc - Little Rock
Connecticut
- Connecticut Clinical Research Institute - Bristol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06851559
The ClinicalTrials.gov registry entry for NCT06851559 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (91% lower). The listed sponsor is Phathom Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06851559 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06851559 about?
NCT06851559 is a clinical study titled "A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks". The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.
What is the current status of trial NCT06851559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-10-30. Estimated completion is 2027-03.
What conditions does trial NCT06851559 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT06851559?
The interventions under investigation include: Placebo (DRUG), Vonoprazan (DRUG).
Who is sponsoring clinical trial NCT06851559?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06851559 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.